{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:43:43Z","timestamp":1786121023036,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04375-z","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:16:38Z","timestamp":1780532198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of triple versus dual inhaled therapy (ICS\/LABA or LABA\/LAMA) for chronic obstructive pulmonary disease: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Weimian","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"3","key":"4375_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccm.2020.06.007","volume":"41","author":"AI Ritchie","year":"2020","unstructured":"Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Chest Med. 2020;41(3):421\u201338.","journal-title":"Clin Chest Med"},{"key":"4375_CR2","doi-asserted-by":"publisher","first-page":"e069679","DOI":"10.1136\/bmj-2021-069679","volume":"378","author":"S Safiri","year":"2022","unstructured":"Safiri S, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990\u20132019: results from the Global Burden of Disease Study 2019. BMJ. 2022;378:e069679.","journal-title":"BMJ"},{"issue":"4","key":"4375_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10389-019-01021-3","volume":"28","author":"A ur Rehman","year":"2020","unstructured":"ur Rehman A, et al. Pharmacological and non-pharmacological management of COPD; limitations and future prospects: a review of current literature. J Public Health. 2020;28(4):357\u201366.","journal-title":"J Public Health"},{"issue":"10","key":"4375_CR4","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.mayocp.2018.05.026","volume":"93","author":"S Mirza","year":"2018","unstructured":"Mirza S, et al. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. 2018;93(10):1488\u2013502.","journal-title":"Mayo Clin Proc"},{"key":"4375_CR5","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.2147\/COPD.S226601","volume":"14","author":"M Kato","year":"2019","unstructured":"Kato M, et al. The IMPACT Study - Single Inhaler Triple Therapy (FF\/UMEC\/VI) Versus FF\/VI And UMEC\/VI In Patients With COPD: Efficacy And Safety In A Japanese Population. Int J Chron Obstruct Pulmon Dis. 2019;14:2849\u201361.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"4375_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12931-021-01777-x","volume":"22","author":"A Koarai","year":"2021","unstructured":"Koarai A, et al. Triple versus LAMA\/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. Respir Res. 2021;22(1):183.","journal-title":"Respir Res"},{"issue":"4","key":"4375_CR7","doi-asserted-by":"publisher","first-page":"e053964","DOI":"10.1136\/bmjopen-2021-053964","volume":"12","author":"A Sicras-Mainar","year":"2022","unstructured":"Sicras-Mainar A, et al. Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study. BMJ open. 2022;12(4):e053964.","journal-title":"BMJ open"},{"key":"4375_CR8","doi-asserted-by":"publisher","first-page":"101531","DOI":"10.1016\/j.cegh.2024.101531","volume":"26","author":"N Jaiswal","year":"2024","unstructured":"Jaiswal N, Field R. Network meta-analysis: the way forward for evidence-based decisions. Clin Epidemiol Global Health. 2024;26:101531.","journal-title":"Clin Epidemiol Global Health"},{"key":"4375_CR9","first-page":"25","volume":"85","author":"PW Jones","year":"1991","unstructured":"Jones PW, Quirk FH, Baveystock CM. The St George\u2019s Respiratory Questionnaire Respiratory Med. 1991;85:25\u201331.","journal-title":"The St George\u2019s Respiratory Questionnaire Respiratory Med"},{"key":"4375_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, et al. netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106:1\u201340.","journal-title":"J Stat Softw"},{"issue":"4","key":"4375_CR11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","volume":"196","author":"DA Lipson","year":"2017","unstructured":"Lipson DA, et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):438\u201346.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"4375_CR12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s12325-020-01266-5","volume":"37","author":"C Wang","year":"2020","unstructured":"Wang C, et al. Efficacy and Safety of Budesonide\/Glycopyrrolate\/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS. Adv Ther. 2020;37(4):1591\u2013607.","journal-title":"Adv Ther"},{"issue":"4","key":"4375_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/15412555.2018.1481022","volume":"15","author":"J Zheng","year":"2018","unstructured":"Zheng J, et al. The Efficacy and Safety of Once-daily Fluticasone Furoate\/Umeclidinium\/Vilanterol Versus Twice-daily Budesonide\/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial). COPD. 2018;15(4):334\u201340.","journal-title":"COPD"},{"issue":"1","key":"4375_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12931-021-01794-w","volume":"22","author":"H Long","year":"2021","unstructured":"Long H, et al. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials. Respir Res. 2021;22(1):209.","journal-title":"Respir Res"},{"issue":"9","key":"4375_CR15","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","volume":"39","author":"AS Ismaila","year":"2022","unstructured":"Ismaila AS, et al. Fluticasone Furoate\/Umeclidinium\/Vilanterol (FF\/UMEC\/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Adv Ther. 2022;39(9):3957\u201378.","journal-title":"Adv Ther"},{"issue":"1","key":"4375_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3\u201378.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"4375_CR17","doi-asserted-by":"publisher","first-page":"e20240412","DOI":"10.36416\/1806-3756\/e20240412","volume":"51","author":"DMG Halpin","year":"2025","unstructured":"Halpin DMG, Singh D. What\u2019s new in the 2025 GOLD report. J Bras Pneumol. 2025;51(1):e20240412.","journal-title":"J Bras Pneumol"},{"key":"4375_CR18","doi-asserted-by":"publisher","first-page":"175346662312086","DOI":"10.1177\/17534666231208630","volume":"17","author":"M Miravitlles","year":"2023","unstructured":"Miravitlles M, Matsunaga K, Dreher M. Stepwise management of COPD: What is next after bronchodilation? Ther Adv Respir Dis. 2023;17:17534666231208630.","journal-title":"Ther Adv Respir Dis"},{"key":"4375_CR19","doi-asserted-by":"crossref","unstructured":"Fukuda N et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2023. 6(6): p. Cd012066.","DOI":"10.1002\/14651858.CD012066.pub3"},{"issue":"4","key":"4375_CR20","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.21037\/jtd.2020.02.51","volume":"12","author":"C Janson","year":"2020","unstructured":"Janson C. Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. J Thorac Dis. 2020;12(4):1561\u20139.","journal-title":"J Thorac Dis"},{"issue":"12","key":"4375_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/17476348.2024.2316167","volume":"17","author":"L Calzetta","year":"2023","unstructured":"Calzetta L, Rogliani P. Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate\/umeclidinium\/vilanterol fixed-dose combination in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2023;17(12):1273\u201383.","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"4375_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/thoraxjnl-2021-217930","volume":"77","author":"C Janson","year":"2022","unstructured":"Janson C. Inhaled corticosteroids in COPD: risk and benefits. Thorax. 2022;77(6):530\u20131.","journal-title":"Thorax"},{"key":"4375_CR23","first-page":"101035","volume":"84","author":"M Zysman","year":"2023","unstructured":"Zysman M, et al. Impact of pharmacological and non-pharmacological interventions on mortality in chronic obstructive pulmonary disease (COPD) patients. Respir Med Res. 2023;84:101035.","journal-title":"Respir Med Res"},{"issue":"1","key":"4375_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12931-019-1262-0","volume":"21","author":"BF Hartley","year":"2020","unstructured":"Hartley BF, et al. Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2020;21(1):5.","journal-title":"Respir Res"},{"key":"4375_CR25","doi-asserted-by":"crossref","unstructured":"Miravitlles M et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev, 2021. 30(160).","DOI":"10.1183\/16000617.0075-2021"},{"issue":"5","key":"4375_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2020.1845314","volume":"22","author":"BL Ritondo","year":"2021","unstructured":"Ritondo BL, et al. Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert Opin Pharmacother. 2021;22(5):611\u201320.","journal-title":"Expert Opin Pharmacother"},{"key":"4375_CR27","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.2147\/COPD.S269637","volume":"15","author":"TP Lodise","year":"2020","unstructured":"Lodise TP, et al. Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies. Int J Chron Obstruct Pulmon Dis. 2020;15:2889\u2013900.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"4375_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12931-021-01789-7","volume":"22","author":"X Pu","year":"2021","unstructured":"Pu X, et al. Association between ICS use and risk of hyperglycemia in COPD patients: systematic review and meta-analysis. Respir Res. 2021;22(1):201.","journal-title":"Respir Res"},{"issue":"1","key":"4375_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12890-023-02602-5","volume":"23","author":"S Peng","year":"2023","unstructured":"Peng S, et al. Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2023;23(1):304.","journal-title":"BMC Pulm Med"},{"key":"4375_CR30","doi-asserted-by":"crossref","unstructured":"Nathan SD et al. Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results. Eur Respir J, 2024. 63(6).","DOI":"10.1183\/13993003.00172-2024"},{"key":"4375_CR31","doi-asserted-by":"crossref","unstructured":"Lee J-H et al. Risk of pneumonia associated with inhaled corticosteroid in patients with chronic obstructive pulmonary disease: a Korean population-based study. Int J Chronic Obstr Pulm Dis, 2020: pp. 3397\u2013406.","DOI":"10.2147\/COPD.S286149"},{"key":"4375_CR32","doi-asserted-by":"crossref","unstructured":"Case MA et al. Guideline Alignment and Medication Concordance in COPD. CHEST Pulm, 2024. 2(1).","DOI":"10.1016\/j.chpulm.2023.100017"},{"issue":"7","key":"4375_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1159\/000515133","volume":"100","author":"HW Lee","year":"2021","unstructured":"Lee HW, et al. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid\/Long-Acting Muscarinic Antagonist\/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis. Respiration. 2021;100(7):631\u201343.","journal-title":"Respiration"},{"issue":"9","key":"4375_CR34","doi-asserted-by":"publisher","first-page":"e036455","DOI":"10.1136\/bmjopen-2019-036455","volume":"10","author":"EL Axson","year":"2020","unstructured":"Axson EL, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMJ Open. 2020;10(9):e036455.","journal-title":"BMJ Open"},{"key":"4375_CR35","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2147\/COPD.S230955","volume":"15","author":"JR Hurst","year":"2020","unstructured":"Hurst JR, et al. Efficacy and Safety of LAMA\/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons. Int J Chron Obstruct Pulmon Dis. 2020;15:1529\u201343.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"4375_CR36","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1513\/AnnalsATS.202001-023OC","volume":"17","author":"MJ Mammen","year":"2020","unstructured":"Mammen MJ, et al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis. Annals Am Thorac Soc. 2020;17(10):1308\u201318.","journal-title":"Annals Am Thorac Soc"},{"key":"4375_CR37","doi-asserted-by":"crossref","unstructured":"Savran O, Ulrik CS. Inhaled Corticosteroid Exposure and Risk of Cataract in Patients with Asthma and COPD: A Systematic Review and Meta-Analysis. J Ophthalmol, 2023. 2023: p. 8209978.","DOI":"10.1155\/2023\/8209978"},{"issue":"18","key":"4375_CR38","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"issue":"10","key":"4375_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respir Med"},{"key":"4375_CR40","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.2147\/COPD.S220850","volume":"14","author":"M Ichinose","year":"2019","unstructured":"Ichinose M, et al. Efficacy and Safety of Budesonide\/Glycopyrrolate\/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study. Int J Chron Obstruct Pulmon Dis. 2019;14:2979\u201391.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04375-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04375-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04375-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T02:38:30Z","timestamp":1786070310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04375-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4375"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04375-z","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All data were obtained from publicly available databases; therefore, institutional review board approval and patient consent were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"342"}}